1. Home
  2. TGHL vs MRKR Comparison

TGHL vs MRKR Comparison

Compare TGHL & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The GrowHub Limited Class A Ordinary Shares

TGHL

The GrowHub Limited Class A Ordinary Shares

HOLD

Current Price

$1.15

Market Cap

18.6M

Sector

Technology

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.27

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGHL
MRKR
Founded
2020
1999
Country
Singapore
United States
Employees
7
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
18.5M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
TGHL
MRKR
Price
$1.15
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
7.5M
58.0K
Earning Date
05-18-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.81
52 Week High
$3.80
$2.46

Technical Indicators

Market Signals
Indicator
TGHL
MRKR
Relative Strength Index (RSI) 64.63 43.00
Support Level $0.37 $1.17
Resistance Level $1.70 $1.54
Average True Range (ATR) 0.20 0.08
MACD 0.03 -0.02
Stochastic Oscillator 51.30 46.14

Price Performance

Historical Comparison
TGHL
MRKR

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: